Joseph M Scandura
Weill Medical College of Cornell University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joseph M Scandura as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04103645 · Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN PatientsWeill Medical College of Cornell University · terminated · Myeloproliferative Neoplasm · principal investigator
- Ph2NCT01627041 · Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI) · active not recruiting · Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Controlling the Niche to Control Clonal HematopoiesisR01HL175556 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · fiscal years 2025 to 2026 · $793,947 awarded in 2026Same name and institution; not confirmed by an ID
- Promoting hematopoietic regeneration after chemo by rescheduling homeostasisR56HL116436 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · fiscal years 2014 · $546,614 awarded in 2014Same name and institution; not confirmed by an ID
- Genome-wide Identification of DNA Methylation Biomarkers in AMLR21CA159175 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · fiscal years 2012 to 2013 · $145,239 awarded in 2013Same name and institution; not confirmed by an ID
- p57KIP2 in Hematopoiesis and LeukemogenesisK08CA104082 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · fiscal years 2005 to 2009 · $134,703 awarded in 2009Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:09 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- 106 citationsRCR 2.4
- Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival.Leukemia · 2021102 citationsRCR 6.8
- MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.J Clin Oncol · 202386 citationsRCR 7.8
- Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.Nat Med · 202563 citationsRCR 15.9
- 59 citationsRCR 1.9
- Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia.Haematologica · 201846 citationsRCR 1.5